Report Overview:
Cerebroprotein Hydrolysate is a neuroprotective medication derived from animal brain proteins, primarily used for treating stroke, traumatic brain injuries, and neurodegenerative disorders like Alzheimer's disease. These formulations work by repairing damaged nerve cells and enhancing neuronal survival through active peptides and amino acids that support brain metabolism.
Market growth is primarily driven by rising neurological disorder prevalence worldwide, particularly in aging populations where conditions like dementia show increasing incidence. According to WHO data, approximately 55 million people currently live with dementia globally, with nearly 10 million new cases annually. While Asia-Pacific dominates consumption due to high stroke incidence rates and improving healthcare access, regulatory concerns about animal-derived ingredients present adoption challenges in western markets. Key manufacturers are investing in purification technologies and alternative production methods to address these limitations.
Market Value:
Global Cerebroprotein Hydrolysate Drug market size was valued at USD 216 million in 2023. The market is projected to grow from USD 237 million in 2025 to USD 411 million by 2030, exhibiting a CAGR of 9.9% during the forecast period. CAGR of 9.9%
(2024 – 2032)
By Applications:
Hospitals
Clinics
Neurology centers
Rehabilitation centers
By Types:
• Tablets
• Capsules
• Others
Key players include:
• Zhitong Biopharma (China)
• Shanxi Pude Pharma (China)
• Harbin Medisan Pharmaceutical (China)
• Hainan Unipul Pharmaceutical (China)
• JiangshiYaoye (China)
• MITS Healthcare Private Limited (India)
